Aim 3 Sample Clauses

Aim 3. Both the Division (1.a above) and the Prevention Science and Methodology Group (PSMG) provide organizational support for this goal. The PSMG network, established 10 years ago and comprising more than 170 researchers and methodologists, conducts interdisciplinary methods presentations through weekly grand-rounds conference calls and facilitatesmethodological development and application in leading edge research nationally. Xx. Xxxxx heads this group, and Xx. Xxxxxxxxx has joined PSMG's steering committee so that it can address the Miami CTSI agenda for developing translational biostatistics research. This Component has also created a small grant program to stimulate cross-school collaborations in methodological development.
AutoNDA by SimpleDocs
Aim 3. Examine Transition Assessment Literature & Identify Transition Factors
Aim 3. Our trainee, Dr. Xxxxx Kenya was selected as one of the four initial CTSI pilot trainees. Her project focuses on use home based Rapid HIV testing as a means to increase HIV screening in underserved African-American communities, one of the priority areas highlighted by the CTSI Community Advisory Board. Medical Student Xxxxxx Xxxxxx, building on a project showing high rates of dirty needles in Miami due to lack of needle exchange programs (another CAB identified community priority), has spearheaded a medical student led State-Wide campaign to write and introduce House and Senate bills in FL allowing for needle exchange programs in the state. This initiative has garnered 500 hours of service from the Florida Medical Association, the full support of our University’s lobbyists, support from over 10 State-wide organizations, Bills introduced in the State House and Senate and committee hearings.
Aim 3. To develop degree-granting and formal early career mentored programs that will expand and diversify the research workforce, with a particular focus on addressing health care disparities and culturally appropriate research methods.
Aim 3. To develop degree-granting and formal early career mentored programs that will expand and diversify the research workforce, with a particular focus on addressing health care disparities and culturally appropriate research methods. i. Established the coursework required and enrolled the first class of students for the Masters in Clinical and Translational Science ii. Enrolled Early Career Investigators into the K12 program. iii. Involved career, scientific and clinical mentors into these programs
Aim 3. We plan to produce a paper on Scientific Equity that maps out design requirements for randomized trials of interventions and strategies for synthesizing findings from the literature related to health disparities. We, along with our collaborators, plan to submit an NIH application to develop the biostatistical and psychometric methodology for extending computerized adaptive testing to minority populations. This method would identify items that display differential item functioning as well as different underlying psychometric structures. We plan to submit this as an extension of measuring depressive, anxious, and bipolar symptoms in a Spanish speaking population as a model that can be generalized to other medical conditions and populations.
Aim 3 a. The RTS-Smartstore DNA storage robotic system, within the Hussman Institute Biorepository is now fully operational and implemented into the Nautilus LIMs system. b. Adoption and development of the NCI-designated ca-Tissue for de-identified biospecimen management, cataloguing, tracking, and distribution with associated clinical data. c. Initiated integration of sample acquisition and tracking between the Genomics Institute and the Cancer Center Tissue Bank Core Facility. d. Initiated discussions with the CTSI Bioinformatics component for the interfacing of the BioResource specimen data with EPIC and the overarching Research Data Environment (URIDE).
AutoNDA by SimpleDocs
Aim 3 i. We will continue working to identify meaningful discoveries (not only medical product candidates, but technologies developed in all of our scientific disciplines across our three UM campuses (e.g. engineering, medicine, physics, marine biology, etc.) and help research teams to develop them, and to advance those discoveries through all the stages required toward commercialization.
Aim 3. To develop an agent-based model evaluating the effectiveness of network-based and individual-targeting behavioral interventions. Evidence on the effectiveness of interventions targeting modifiable health behaviors for CVD prevention are mixed and, to date, no existing study comprehensively evaluated the potential effectiveness of different types of behavioral interventions. Different from existing studies, this dissertation aims to use a systems science approach to comprehensively evaluate the effectiveness of two major types of behavioral interventions – network-based intervention (e.g. popular opinion leader intervention) and individual-targeting intervention (e.g. incentivizing healthy behaviors), incorporating theories of individual behavioral choices and intervention diffusion on a social network. Through a combination of observational studies and computational experiments, this dissertation will address the following questions: 1). What are the network-level and individual-level contributing factors to individual’s health behaviors throughout life-course; 2) Given the knowledge of community network structure, target population characteristics and established community behavioral norms, what type of intervention and target population selection strategy would be most effective in maximizing the prevalence of health-benefiting behaviors in the long run; 3) Given specific target population’s characteristics, what type of data would be needed in the future behavioral intervention design and effectiveness evaluation? This dissertation will be the first to summarize major behavioral intervention strategies into computational model designs with pre-specified target population selection and model set-up to alter individual incentives. Also, different from prior research(76– 78) that centered around the influence of direct network connections (peer influence) on individual’s health behavior, this dissertation will evaluate the population-level impact of different intervention scenarios, conditioning upon both network-based diffusion processes and operationalized individual incentive as individual behavioral choice utility functions. Most importantly, this dissertation provides an opportunity to compare and contrast the empirical and systems science modeling approach for identifying causal mechanisms linking individual and network level factors to population level outcomes of complex behavioral interventions. Findings from this dissertation will motivate future...

Related to Aim 3

  • Technology Research Analyst Job# 1810 General Characteristics

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • SMT XXXXXX XXXXXXXX, daughter of Sri Pawan Kumar Xxxxxxxx, by occupation – Housewife, (4) XXXXXXX XXXXXXXX, daughter of Sri Pawan Kumar Xxxxxxxx, by occupation – Others , all are by faith – Hindu, by Nationality – Indian, all are residing at Radhanagar Road, P.O. Burnpur, P.S. – Haripur, District – Burdwan, presently residing at Kamalgazi, P.S. Sonarpur, Kolkata – 700103, SRI PAWAN KUMAR XXXXXXXX, SMT. XXXXXXX XXXX XXXXXXXX, SMT. XXXXXX XXXXXXXX and XXXXXXX XXXXXXXX all are being represented by their Constituted Attorney, “M/S. RAJWADA GROUP” (PAN- XXXXX0000X), a Partnership Firm having its registered office at 00, Xxxxxxxx Xxxxxx Xxxx, Xxxxxxxxxxxx, Xxxxx, P.S. Sonarpur, Kolkata -700 084, duly represented by its authorised signatory SRI XXXXXX XXXXXXX (PAN- XXXXX0000X), son of Late Xxxxxxxx Xxxxx Agarwal, by faith- Hindu, by Nationality- Indian, by occupation-Business, residing at 00, Xxxxxxxx Xxxxxx Xxxx, Xxxxxxxxxxxx, Xxxxx, Police Station Sonarpur, Kolkata- 700 084, and also residing at “Narendra Bhawan”, Kamalgazi, Post Office- Narendrapur, Police Xxxxxxx Xxxxxxxx, Xxxx Xxxxx 00 Xxxxxxxx, Xxxxxxx – 700103, by virtue of a Development Power of Attorney which was duly registered on 25th March, 2015, before the office of the D.S.R. IV, South 24 Parganas at Alipore which is recorded in its Book Xx. 0, XX Xxxxxx Xx. 0, pages from 5832 to 5845, Being no. 02580 for the year 2015, hereinafter called and referred to as the “OWNERS/VENDORS” (which term or expression shall unless excluded by or repugnant to the context be deemed to mean and include their heirs, executors, administrators, legal representatives and assigns) of the FIRST PART. “M/S. RAJWADA GROUP” (PAN- XXXXX0000X), a Partnership firm having its registered office at 00, Xxxxxxxx Xxxxxx Xxxx, Xxxxxxxxxxxx, Post Office- Garia, P.S. Sonarpur, Kolkata – 700084, duly represented by its represented by one of its Partners and Constituted Attorney by virtue of registered General Power of Attorney dated 29.01.2015, registered at the Office of the Additional District Sub Registrar at Garia and recorded in Book No. IV, CD. Volume No. I, Pages from 207 to 216, Being No. 00021 for the year 2015 namely, SRI XXXXXX XXXXXXX, son of Late Xxxxxxxx Xxxxx Agarwal, by occupation- Business, by religion- Hindu, by- Nationality- Indian, residing at 00, Xxxxxxxx Xxxxxx Xxxx, Xxxxxxxxxxxx, Xxxxx, Post Office-Garia, Police Station-Sonarpur, Kolkata-700 084, hereinafter collectively referred to as the ‘DEVELOPER’ (which expression shall unless excluded by or repugnant to the context be deemed to mean and include his heirs, executors, administrators, legal representatives, and assigns) of the SECOND PART. ………, by religion - ……….., by Nationality- ……….., by occupation- ……………, residing at …………………., hereinafter called and referred to as the “PURCHASER” (which term or expression shall unless excluded by or repugnant to the context be deemed to mean and include his/her/their heirs executors, administrators, legal representatives and assigns) of the THIRD PART.

  • Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!